

11. a sustained-release composition according to claim 3, wherein the LH-RH derivative is a peptide represented by the formula:

5-oxo-Pro-His-Trp-Ser-Tyr-Y-Leu-Arg-Pro-Z

wherein Y represents DLeu, DAla, DTrp, DSer(tBu), D2Nal or DHis(ImBzl); Z represents NH-C<sub>2</sub>H<sub>5</sub> or Gly-NH<sub>2</sub>.

12. a sustained-release composition according to  
5 claim 6, wherein the terminal carboxyl group content of the polymer is 50-90 micromol per unit mass (gram) of the polymer.

13. a sustained-release composition according to  
10 claim 3, wherein the molar ratio of the hydroxynaphthoic acid or salt thereof and the LH-RH derivative or salt thereof is from 3 to 4 to 4 to 3.

14. a sustained-release composition according to  
claim 13, wherein the LH-RH derivative or salt thereof is contained at 14% (w/w) to 24% (w/w).

15 15. a sustained-release composition according to  
claim 1, wherein the bioactive substance or salt thereof is very slightly soluble in water or soluble in water.

16. a sustained-release composition according to  
claim 1, which is intended for injection.

20 17. a method of producing the sustained-release  
composition according to claim 1, comprising removing the solvent from a mixture of a bioactive substance or salt thereof, a biodegradable polymer or salt thereof, and hydroxynaphthoic acid or a salt thereof.

25 18. a method of producing the sustained-release  
composition according to claim 17, comprising mixing and dispersing a bioactive substance or salt thereof in an organic solvent solution containing a biodegradable polymer or salt thereof and hydroxynaphthoic acid or a  
30 salt thereof, and subsequently removing the organic solvent.

19. a method of producing the sustained-release  
composition according to claim 18, wherein the bioactive  
substance or salt thereof is in the form of an aqueous  
35 solution.

20. a production method according to claim 17,

wherein the salt of the bioactive substance is a salt with a free base or acid.

21. a pharmaceutical containing the sustained-release composition according to claim 1.

22. an agent for preventing or treating of prostatic cancer, prostatic hypertrophy, endometriosis, hysteromyoma, metrofibroma, precocious puberty, dysmenorrhea, or breast cancer, or a contraceptive, containing the sustained-release composition according to claim 3.

10 23. a sustained-release composition containing the hydroxynaphthoate of a bioactive substance and a biodegradable polymer or salt thereof.

15 24. a method of suppressing bioactive substance initial burst from a sustained-release composition, comprising using hydroxynaphthoic acid or a salt thereof.

25 25. a method of increasing the efficiency of bioactive substance inclusion in a sustained-release composition, comprising using hydroxynaphthoic acid or a salt thereof.

20 26. a hydroxynaphthoate of a bioactive peptide.

27. a hydroxynaphthoate of a bioactive peptide according to claim 26 which is soluble in water or very slightly soluble in water.

28. a sustained-release composition containing the hydroxynaphthoate of a bioactive peptide.

add c27